Drugs / Pinatuzumab Vedotin
Pinatuzumab Vedotin
also known as
ACD-22-VCMMAE · DCDT2980S · FCU-2703 · pina · Pinatuzumab vedotina · Pinatuzumab vedotine · RG-7593 · RO-5541072-000
targets CD22
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01209130 | Oct 2010 → Mar 2015 | lymphoid neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01691898 | Sep 2012 → Mar 2017 | diffuse large B-cell lymphoma, follicular lymphoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pinatuzumab Vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01691898 ↗ |
| Known as | ACD-22-VCMMAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Known as | DCDT2980S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01209130 ↗ |
| Known as | FCU-2703 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Known as | pina | “Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials.” PMID 30935953 ↗ Mar 2019 |
| Known as | Pinatuzumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Known as | Pinatuzumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Known as | RG-7593 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Known as | RO-5541072-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301585 ↗ |
| Modality | Other / unclassified | “Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials.” PMID 30935953 ↗ Mar 2019 |
| Route | Intravenous | “DCDT2980S administered by intravenous (IV) infusion” NCT01209130 ↗ |
| Target | CD22 | “CD22 binding agent” CHEMBL3301585 ↗ |